Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“KRAS alert!
Great to see our latest collaborative effort led by Chiara Ambrogio Lab, published in Cancer Discovery AACR Journals
Here, we demonstrate that acquired EML4ALK rearrangements can drive resistance to KRAS G12C (OFF) inhibitors by restoring RAS signaling through wild-type RAS.
These findings highlight an additional therapeutic opportunity for multi-selective RAS inhibitors currently under clinical investigation, as well as rational combination strategies incorporating ALK and RAS inhibitors.”
Title: EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway
Authors: Pietro Scaparone, Alessia Mira, Taek-Chin Cheong, Enrico Patrucco, Biagio Ricciuti, Riccardo Gribaudo, Edoardo Garbo, Rossella Scardaci, Ilenia Savinelli, Sandra Vietti Michelina, Igor Odintsov, Elliott Brea, Roberto Mignacco, Rafael Blasco, David Santamaría, Claudia Voena, Marco Hofmann, Ernest Nadal, Silvia Novello, Mark Awad, Roberto Chiarle, Chiara Ambrogio
Read the Full Article on Cancer Discovery
Other articles about Biagio Ricciuti on OncoDaily